Why the study?
Does cardiac resynchronization therapy improve clinical status and mortality in patients with symptomatic heart failure resulting from systolic dysfunction?
Does cardiac resynchronization therapy improve clinical status and mortality in patients with symptomatic heart failure resulting from systolic dysfunction?
This advisory outlines appropriate patient selection criteria for cardiac resynchronization therapy based on clinical trial evidence showing improved clinical status and mortality in heart failure with systolic dysfunction.
Answers are grounded in this paper and cite their sources.
CRT should be considered in selected systolic HF patients; reinforces Level 1 guideline recommendations.
Cardiac resynchronization therapy (CRT) is a relatively new therapy for patients with symptomatic heart failure resulting from systolic dysfunction. CRT is achieved by simultaneously pacing both the left and right ventricles. Biventricular pacing resynchronizes the timing of global left ventricular depolarization and improves mechanical contractility and mitral regurgitation. Published clinical trials have demonstrated that CRT results in improved clinical status and lower mortality rate when selected patients with systolic ventricular dysfunction and heart failure are treated with CRT. This advisory identifies appropriate candidates for CRT on the basis of the inclusion criteria and results from the published clinical trials.
No takes yet. Share an insight, caveat, or question.
Strickberger et al. (2005) conducted a review in Symptomatic heart failure resulting from systolic dysfunction. Cardiac resynchronization therapy (CRT) was evaluated. Cardiac resynchronization therapy improves clinical status and lowers mortality in selected patients with systolic ventricular dysfunction and heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: